Circular RNA circ_0026218 Suppressed Atherosclerosis Progression via miR-338-3p/SIRT6 Axis.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
07
2022
accepted:
14
10
2022
entrez:
3
2
2023
pubmed:
4
2
2023
medline:
7
2
2023
Statut:
epublish
Résumé
Multiple circular RNAs (circRNAs) are implicated in atherosclerosis (AS) pathogenesis. In fact, how circRNA 0026218 (circ_0026218) functions in AS remains unknown, and thus the functions and mechanisms of circ_0026218 in the injury of vascular endothelial cells are to be investigated. Microarray analysis was employed to screen out differentially expressed circRNAs in AS. A cell model was mimicked by treating Human umbilical vein endothelial cells (HUVECs) with oxidized low-density lipoprotein (ox-LDL). circ_0026218, microRNA-338-3p (miR-338-3p) and silent information regulator 6 (SIRT6) expressions in HUVECs with ox-LDL treatment were probed by qRT-PCR. The cell proliferative capabilities were exposed by CCK-8 assay. The contents of interleukin 6 (IL-6), interleukin 1 circ_0026218 was greatly depleted in ox-LDL-stimulated HUVECs. circ_0026218 overexpression promoted viability of HUVECs Collectively, circ_0026218 upregulates SIRT6 expression through decoying miR-338-3p, thereby inhibiting ox-LDL-initiated injury of HUVECs. circ_0026218 is involved in the pathogenesis of AS.
Sections du résumé
Background
UNASSIGNED
Multiple circular RNAs (circRNAs) are implicated in atherosclerosis (AS) pathogenesis. In fact, how circRNA 0026218 (circ_0026218) functions in AS remains unknown, and thus the functions and mechanisms of circ_0026218 in the injury of vascular endothelial cells are to be investigated.
Methods
UNASSIGNED
Microarray analysis was employed to screen out differentially expressed circRNAs in AS. A cell model was mimicked by treating Human umbilical vein endothelial cells (HUVECs) with oxidized low-density lipoprotein (ox-LDL). circ_0026218, microRNA-338-3p (miR-338-3p) and silent information regulator 6 (SIRT6) expressions in HUVECs with ox-LDL treatment were probed by qRT-PCR. The cell proliferative capabilities were exposed by CCK-8 assay. The contents of interleukin 6 (IL-6), interleukin 1
Results
UNASSIGNED
circ_0026218 was greatly depleted in ox-LDL-stimulated HUVECs. circ_0026218 overexpression promoted viability of HUVECs
Conclusion
UNASSIGNED
Collectively, circ_0026218 upregulates SIRT6 expression through decoying miR-338-3p, thereby inhibiting ox-LDL-initiated injury of HUVECs. circ_0026218 is involved in the pathogenesis of AS.
Identifiants
pubmed: 36733404
doi: 10.1155/2023/5647758
pmc: PMC9889145
doi:
Substances chimiques
RNA, Circular
0
Tumor Necrosis Factor-alpha
0
Glycosyltransferases
EC 2.4.-
Sirtuins
EC 3.5.1.-
MicroRNAs
0
Lipoproteins, LDL
0
SIRT6 protein, human
EC 3.5.1.-
MIRN338 microRNA, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5647758Informations de copyright
Copyright © 2023 Liang Yang et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
J Cell Physiol. 2019 May;234(5):5588-5600
pubmed: 30341894
Aging (Albany NY). 2018 Sep 6;10(9):2266-2283
pubmed: 30187887
Nat Rev Mol Cell Biol. 2017 Aug;18(8):477-494
pubmed: 28537573
Mol Med Rep. 2021 Jul;24(1):
pubmed: 33982782
Front Genet. 2021 Mar 24;12:632164
pubmed: 33841499
Cell Death Dis. 2016 Jun 02;7(6):e2248
pubmed: 27253412
Antioxid Redox Signal. 2018 Mar 10;28(8):711-732
pubmed: 28661724
Minerva Med. 2021 Aug;112(4):531-533
pubmed: 31578840
Exp Cell Res. 2020 Feb 1;387(1):111744
pubmed: 31759967
Cancer Lett. 2017 Jun 28;396:138-144
pubmed: 28342987
RNA Biol. 2017 Aug 3;14(8):992-999
pubmed: 27617908
Nat Med. 2014 Apr;20(4):368-76
pubmed: 24584117
Cell Transplant. 2020 Jan-Dec;29:963689720963948
pubmed: 33028110
Int J Clin Exp Pathol. 2018 Apr 01;11(4):2256-2267
pubmed: 31938338
Onco Targets Ther. 2020 May 22;13:4545-4558
pubmed: 32547085
J Cell Biol. 2015 Apr 13;209(1):13-22
pubmed: 25869663
Ir J Med Sci. 2022 Jun;191(3):1153-1159
pubmed: 34251586
Perfusion. 2022 Jan;37(1):86-94
pubmed: 33300444
Mol Biotechnol. 2021 Sep;63(9):840-848
pubmed: 34100182
PLoS One. 2013 Dec 05;8(12):e80738
pubmed: 24339880
Circ Res. 2021 Feb 19;128(4):474-491
pubmed: 33353368
J Cell Physiol. 2019 Jul;234(7):11577-11586
pubmed: 30556591
Cell Death Dis. 2021 Jan 12;12(1):77
pubmed: 33436551
Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):107-115
pubmed: 31852304
Med Res Rev. 2021 Mar;41(2):1089-1137
pubmed: 33325563
Life Sci. 2022 Mar 15;293:120306
pubmed: 35016883
Sci Signal. 2015 Mar 17;8(368):re3
pubmed: 25783160
Cell Death Dis. 2018 May 9;9(5):522
pubmed: 29743567
J Am Coll Cardiol. 2017 Jul 11;70(2):212-229
pubmed: 28683969
Front Genet. 2021 Feb 02;12:590633
pubmed: 33603770
Trends Endocrinol Metab. 2017 Mar;28(3):168-185
pubmed: 27836583
Eur Heart J. 2014 Apr;35(15):999-1006
pubmed: 24046434
Braz J Med Biol Res. 2021 Jan 15;54(3):e9386
pubmed: 33470395
FEBS J. 2017 May;284(9):1324-1337
pubmed: 28296196
BMC Cardiovasc Disord. 2021 Feb 2;21(1):51
pubmed: 33526034